107 related articles for article (PubMed ID: 16595812)
1. Safety of high-dose iron sucrose infusion in hospitalized patients with chronic kidney disease.
Hollands JM; Foote EF; Rodriguez A; Rothschild J; Young S
Am J Health Syst Pharm; 2006 Apr; 63(8):731-4. PubMed ID: 16595812
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of total-dose iron sucrose infusions in patients with iron deficiency anemia.
Wall GC; Pauly RA
Am J Health Syst Pharm; 2008 Jan; 65(2):150-3. PubMed ID: 18192261
[TBL] [Abstract][Full Text] [Related]
3. Utilization trends and safety of intravenous iron replacement in pediatric specialty care: A large retrospective cohort study.
Boucher AA; Pfeiffer A; Bedel A; Young J; McGann PT
Pediatr Blood Cancer; 2018 Jun; 65(6):e26995. PubMed ID: 29369486
[TBL] [Abstract][Full Text] [Related]
4. Effects of an accelerated intravenous iron regimen in hospitalized patients with advanced heart failure and iron deficiency.
Reed BN; Blair EA; Thudium EM; Waters SB; Sueta CA; Jensen BC; Rodgers JE
Pharmacotherapy; 2015 Jan; 35(1):64-71. PubMed ID: 25556867
[TBL] [Abstract][Full Text] [Related]
5. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA
J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial.
Van Wyck DB; Cavallo G; Spinowitz BS; Adhikarla R; Gagnon S; Charytan C; Levin N
Am J Kidney Dis; 2000 Jul; 36(1):88-97. PubMed ID: 10873877
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
8. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial.
Onken JE; Bregman DB; Harrington RA; Morris D; Buerkert J; Hamerski D; Iftikhar H; Mangoo-Karim R; Martin ER; Martinez CO; Newman GE; Qunibi WY; Ross DL; Singh B; Smith MT; Butcher A; Koch TA; Goodnough LT
Nephrol Dial Transplant; 2014 Apr; 29(4):833-42. PubMed ID: 23963731
[TBL] [Abstract][Full Text] [Related]
9. Safety profiles of total dose infusion of low-molecular-weight iron dextran and high-dose iron sucrose in renal patients.
Atalay H; Solak Y; Acar K; Govec N; Turk S
Hemodial Int; 2011 Jul; 15(3):374-8. PubMed ID: 21564503
[TBL] [Abstract][Full Text] [Related]
10. Treatment of childhood-onset restless legs syndrome and periodic limb movement disorder using intravenous iron sucrose.
Grim K; Lee B; Sung AY; Kotagal S
Sleep Med; 2013 Nov; 14(11):1100-4. PubMed ID: 23993871
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review.
Qunibi WY
Arzneimittelforschung; 2010; 60(6a):399-412. PubMed ID: 20648931
[TBL] [Abstract][Full Text] [Related]
12. Retrospective Safety Evaluation of a Pharmacist-Assisted Total Dose Iron Sucrose Protocol in Hospital Inpatients With Iron Deficiency Anemia.
Wall G; Sharma V; Taylor MJ; Schneider R; Adams K; Gasperi L; Lukenbill JC
J Pharm Pract; 2021 Aug; 34(4):573-576. PubMed ID: 31665957
[TBL] [Abstract][Full Text] [Related]
13. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products.
Charytan C; Schwenk MH; Al-Saloum MM; Spinowitz BS
Nephron Clin Pract; 2004; 96(2):c63-6. PubMed ID: 14988600
[TBL] [Abstract][Full Text] [Related]
14. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
15. Safety of iron polymaltose given as a total dose iron infusion.
Newnham E; Ahmad I; Thornton A; Gibson PR
Intern Med J; 2006 Oct; 36(10):672-4. PubMed ID: 16958647
[TBL] [Abstract][Full Text] [Related]
16. The comparative safety of various intravenous iron preparations in chronic kidney disease patients.
Anirban G; Kohli HS; Jha V; Gupta KL; Sakhuja V
Ren Fail; 2008; 30(6):629-38. PubMed ID: 18661414
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Adverse Events and Intravenous Iron Infusion Formulations in Adults With and Without Prior Infusion Reactions.
Arastu AH; Elstrott BK; Martens KL; Cohen JL; Oakes MH; Rub ZT; Aslan JJ; DeLoughery TG; Shatzel J
JAMA Netw Open; 2022 Mar; 5(3):e224488. PubMed ID: 35353168
[TBL] [Abstract][Full Text] [Related]
18. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
19. Intravenous iron sucrose: establishing a safe dose.
Chandler G; Harchowal J; Macdougall IC
Am J Kidney Dis; 2001 Nov; 38(5):988-91. PubMed ID: 11684551
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial.
Charytan C; Levin N; Al-Saloum M; Hafeez T; Gagnon S; Van Wyck DB
Am J Kidney Dis; 2001 Feb; 37(2):300-7. PubMed ID: 11157370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
